Dr. Svensson on PD-1/PD-L1 Status in Esophageal and Gastric Adenocarcinoma

Video

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the receptor PD-1 as it relates to MMR status.

Results showed that PD-1 expression was not associated with MMR status, Svensson says. Although, the expression of PD-L1 in both tumor cells and tumor-infiltrating immune cells was significantly associated with MMR deficiency (P < .001 for both). Neither PD-L1 expression or MMR status in tumor cells was prognostic, whereas high PD-1 expression (10%) in tumor infiltrating immune cells was associated with prolonged overall survival (P = .012), Svennsson adds.

<<< View more from the 2018 GI Cancer Symposium

Related Videos
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Michael Iglesia, MD, PhD
Kian-Huat Lim, MD, PhD